All 30 subjects completed the trial without any adverse events. The ages of the 30 subjects ranged from 49 to 74 years (average age: 56.2 yrs), and their body weights ranged from 47 to 75 kg (average weight: 58.8 kg). In the lower-dose group (n=15), the average age was 57.8±7.1 years and the average weight was 55.9±5.8 kg; in the higher-dose group (n=15), the average age was 54.5±6.3 years and the average weight was 61.8±8.8 kg. By the Mann-Whitney test, there was no significant difference in the ages and body weights between the 2 groups, and so the selection of subjects was deemed appropriate. No subjective adverse events were reported. The laboratory evaluations revealed no significant abnormalities in the CBC, the LFTs and the urinalysis.